Showing 2181-2190 of 2314 results for "".
- TopiVert Announces Topline Results from Phase 2b/3 Study of Dry Eye Disease Drug Candidatehttps://modernod.com/news/topivert-announces-topline-results-from-theia-1-phase-2b-3-clinical-study-of-top1630-as-a-treatment-for-dry-eye-disease/2476792/TopiVert Pharma announced topline results from THEIA-1 phase 2b/3 clinical study evaluating TOP1630, a novel anti-inflammatory kinase inhibitor, as an ophthalmic solution for the treatment of dry eye disease. THEIA-1, a multicenter, randomized, double-masked, placebo-controlled phase 2b/3
- EssilorLuxottica, Maker of Ray-Ban Sunglasses, Agrees to Buy GrandVision in $8 Billion Dealhttps://modernod.com/news/ray-ban-maker-agrees-to-buy-grandvision-for-8-billion/2479558/A blockbuster deal in the eyecare retail space was announced on Wednesday as EssilorLuxottica, the maker of Ray-Ban sunglasses, agreed to buy Dutch retailer GrandVision NV in multi-billion dollar deal. Paris-based EssilorLuxottica agreed to buy control (77%) of European rival GrandVision f
- Bausch + Lomb Introduces 23-Gauge Bi-Blade Dual Port Vitrectomy Cutter for the Stellaris Elite Vision Enhancement Systemhttps://modernod.com/news/bausch-lomb-introduces-23-gauge-bi-blade-dual-port-vitrectomy-cutter-for-the-stellaris-elite-vision-enhancement-system/2476752/Bausch + Lomb announced the introduction of the 23-gauge Bi-Blade dual port vitrectomy cutter for the Stellaris Elite vision enhancement system. The new probe joins the available 25- and 27-gauge Bi-Blade cutters as options in the Bi-Blade portfolio. All Bi-Blade cutters double effective cut rate
- New Software Update Expands Capabilities of the OD-OS Navilas 577shttps://modernod.com/news/new-software-update-expands-capabilities-of-the-od-os-navilas-577s/2476754/OD-OS has released a new software update for its Navilas 577s. With a new multimodal “export wizard,” retina specialists can generate high resolution images of their treatments in different configurations. This allows for advanced, transparent documentation for all purposes and record
- Eye Specialist Works to Prevent Motor Vehicle Related Traumatic Eye Injurieshttps://modernod.com/news/eye-specialist-works-to-prevent-motor-vehicle-related-traumatic-eye-injuries/2476751/Within a 6-week period, Grady Memorial Hospital eye specialist Yousuf Khalifa, MD, witnessed an unusual set of traumatic eye injuries. Three patients, all riding with their windows down, suffered serious eye injuries when the glass in their exterior rear-facing side
- Nicox Announces Completes Enrollment in NCX 470 Phase 2 Clinical Studyhttps://modernod.com/news/nicox-announces-completion-of-enrollment-in-ncx-470-phase-2-clinical-study-with-topline-results-on-track-for-early-4q-2019/2476734/Nicox SA announced that it has completed enrollment of patients in its multicenter, phase 2 clinical study evaluating NCX 470 nitric oxide (NO)-donating bimatoprost analog being tested in patients with open-angle glaucoma or ocular hypertension for its ability to lower IOP. This study is a head-t
- Aerie Pharmaceuticals Completes Enrollment of the Netarsudil Phase 2 Clinical Trial in Japan Ahead of Schedulehttps://modernod.com/news/aerie-pharmaceuticals-completes-enrollment-of-the-netarsudil-phase-2-clinical-trial-in-japan-ahead-of-schedule/2479568/Aerie Pharmaceuticals announced that enrollment for its phase 2 clinical trial of netarsudil ophthalmic solution in Japan is complete, a milestone reached several months earlier than previously anticipated. The first patients to enter this prospective, double-masked, multicenter, placebo-
- NuSight Medical Announces Issuance of U.S. Patent Covering the NuLids System for Treating Dry Eye Diseasehttps://modernod.com/news/nusight-medical-announces-issuance-of-u-s-patent-covering-the-nulids-system-for-treating-dry-eye-disease/2476697/NuSight Medical, a medical device company focused on the doctor directed, at-home treatment of dry eye disease, announced that the U.S. Patent Office has issued Patent No. 10,314,763, which is directed to methods related to the treatment of dry eye disease. U.S. Patent No. 10,314,763 cover
- Alan R. Morse, JD, PhD, Vision and Healthcare Services Innovator, Will Retire As President & CEO of Lighthouse Guildhttps://modernod.com/news/alan-r-morse-jd-phd-vision-and-healthcare-services-innovator-will-retire-as-president-ceo-of-lighthouse-guild/2476695/James M. Dubin, Chairman of the Board of Lighthouse Guild, announced that Alan R. Morse, JD, PhD, will be stepping down later this year as President & CEO of Lighthouse Guild after an extraordinary career of almost 52 years as a leader and innovator in the field
- EyecareLive Unveils Enhanced Responsible Telemedicine Platform for Optometry and Ophthalmologyhttps://modernod.com/news/eyecarelive-unveils-enhanced-responsible-telemedicine-platform-for-optometry-and-ophthalmology/2476674/EyecareLive announced the release of EyecareLive 2.0. EyecareLive was built by doctors, for doctors, with a mission to strengthen the doctor-patient relationship by providing a comprehensive telemedicine platform that enhances patient care. The launch will also feature EyecareLive’s